Hepatocellular carcinoma risk assessment using gadoxetic acid-enhanced hepatocyte phase magnetic resonance imaging

Hepatology Research

Volumn 44, Issue 13, 2014, Pages 1339-1346

  Komatsu, Nobutoshi ^a   Motosugi, Utaroh ^a   Maekawa, Shinya ^a   Shindo, Kuniaki ^a   Sakamoto, Minoru ^a   Sato, Mitsuaki ^a   Tatsumi, Akihisa ^a   Miura, Mika ^a   Amemiya, Fumitake ^a   Nakayama, Yasuhiro ^a   Inoue, Taisuke ^a   Fukasawa, Mitsuharu ^a   Uetake, Tomoyoshi ^a   Ohtaka, Masahiko ^a   Sato, Tadashi ^a   Asahina, Yasuhiro ^b   Kurosaki, Masayuki ^c   Izumi, Namiki ^c   Ichikawa, Tomoaki ^a   Araki, Tsutomu ^a   Enomoto, Nobuyuki ^a   more..

^a UNIVERSITY OF YAMANASHI   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c MUSASHINO RED CROSS HOSPITAL   (Japan)

Author keywords

Gadoxetic acid; Hepatocellular carcinoma; Hepatocyte phase; Magnetic resonance imaging; Risk assessment

Indexed keywords

GADOXETIC ACID;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; KAPLAN MEIER METHOD; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NODULE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE COUNT;

EID: 84927573971     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12309     Document Type: Article

References (27)

1. Ichikawa T, Saito K, Yoshioka N etal. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 2010; 45: 133-141.
2. Halavaara J, Breuer J, Ayuso C etal. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT - a multicenter trial. J Comput Assist Tomogr 2006; 30: 345-354.
3. Hamm B, Staks T, Muhler A etal. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195: 785-792.
4. Hammerstingl R, Huppertz A, Breuer J etal. European EOB-study group. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008; 18: 457-467.
5. Huppertz A, Balzer T, Blakeborough A etal. European EOB Study Group. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004; 230 (1): 266-275.
6. Di Martino M, Marin D, Guerrisi A etal. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology 2010; 256: 806-816.
7. Inoue T, Kudo M, Komuta M etal. Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol 2012; 47: 1036-1047.
8. Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to dynamic MRI in the detection of hypovascular small (
9. Kumada T, Toyoda H, Tada T etal. Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol 2011; 197 (1): 58-63.
10. Motosugi U, Ichikawa T, Sano K etal. Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. J Magn Reson Imaging 2011; 34 (1): 88-94.
11. Kim YK, Lee WJ, Park MJ, Kim SH, Rhim H, Choi D. Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC. Radiology 2012; 265 (1): 104-114.
12. Hyodo T, Murakami T, Imai Y etal. Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. Radiology 2013; 266: 480-490.
13. Bartolozzi C, Battaglia V, Bargellini I etal. Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers. Abdom Imaging 2013; 38: 290-296.
14. Golfieri R, Grazioli L, Orlando E etal. Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration. J Magn Reson Imaging 2012; 36: 648-657.
15. Sano K, Ichikawa T, Motosugi U etal. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 2011; 261: 834-844.
16. Motosugi U. Hypovascular hypointense nodules on hepatocyte phase gadoxetic acid-enhanced MR images: too early or too progressed to determine hypervascularity. Radiology 2013; 267 (1): 317-318.
17. Asayama Y, Yoshimitsu K, Nishihara Y etal. Arterial blood supply of hepatocellular carcinoma and histologic grading: radiologic-pathologic correlation. AJR Am J Roentgenol 2008; 190 (1): W28-34.
18. Motosugi U, Ichikawa T, Sou H etal. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 2009; 30: 1042-1046.
19. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
20. Motosugi U, Ichikawa T, Araki T. Rules, roles, and room for discussion in gadoxetic acid-enhanced magnetic resonance liver imaging: current knowledge and future challenges. Magnetic Rsonance in Medical Sciences. 2013; 12: 161-175.
21. Kitao A, Zen Y, Matsui O etal. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging - correlation with molecular transporters and histopathologic features. Radiology 2010; 256: 817-826.
22. Narita M, Hatano E, Arizono S etal. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009; 44: 793-798.
23. Nasu K, Kuroki Y, Tsukamoto T, Nakajima H, Mori K, Minami M. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. American Journal of Roentgenology 2009; 193: 438-444.
24. Degos F, Christidis C, Ganne-Carrie N etal. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47 (1): 131-136.
25. Tarao K, Rino Y, Ohkawa S etal. Association between high serum alanine aminotransferase levels and more rapid development and higher rates of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 1999; 86: 589-595.
26. Ikeda K, Saitoh S, Suzuki Y etal. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930-938.
27. Ikeda K, Saitoh S, Koida I etal. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18 (1): 47-53.